To DNA or not to DNA? That Is the Question, When It Comes to Molecular Subtyping for the Clinic!

摘要: Genome-wide RNA expression profiling has yielded tumor subtypes with strong predictive or prognostic value for a wide variety of cancers. Recently, breast cancer two classifiers have been adopted by the World Health Organization (WHO) and approved Food Drug Administration (FDA). Also on basis DNA copy number profiles, different prognosis described, but not yet led to clinical implementation. The genomic revolution caused next generation sequencing samples presents additional mutation, balanced translocations, single-nucleotide polymorphisms (SNP), neutral loss heterozygosity data simultaneously. We foresee further boost potential in clinic when these multidimensional factors will be implemented. Here we evaluate current stratification power numbers. In training validation approach using 400 published samples, show that classifier accurately classifies subtypes. consider this an important step forward implementation subtyping discuss extra dimensions upcoming techniques bring palette. Clin Cancer Res; 17(15); 4959–64. ©2011 AACR .